Our Firm has received a number of inquiries from Lipitor patients interested in joining this litigation. We are pleased that the proceeding is moving forward.
New York, New York (PRWEB) September 24, 2014
Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) filed on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin are moving forward in the federal litigation underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to a Case Management Order issued on September 22, 2014, attorneys for the defense have been barred from meeting ex parte with treating or prescribing healthcare providers, unless they have permission of plaintiffs’ counsel. Ex parte meetings between plaintiffs’ attorneys and these providers are permitted, so long as they disclose if certain records or documents are discussed, and provide copies of those documents to the defense. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm has received a number of inquiries from Lipitor patients interested in joining this litigation. We are pleased that the proceeding is moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Allegations
Court documents indicate that more than 1,200 Lipitor lawsuits have been filed in the federal multidistrict litigation on behalf of plaintiffs who allege the medication increases the risk that a patient will develop Type 2 diabetes. The Lipitor diabetes litigation has been growing since February 2012, when the U.S. Food & Drug Administration ordered Pfizer, Inc. and other statin manufacturers to add new information about this potential risk to the drugs’ labels.
Among other things, Lipitor lawsuits accuse Pfizer of being aware the association between the medication and diabetes, and of concealing this knowledge from doctors and patients. Plaintiffs further maintain that the label changes made by Pfizer were inadequate, and still do not sufficiently warn Lipitor users that they may be at increased risk for Type 2 diabetes.
Alleged victims of Lipitor and diabetes may be entitled to file their own legal claim against Pfizer. Learn more about pursuing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com